source
- Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectationsMedicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
- Experts call for licensing framework as Utah pauses AI chatbot prescription programAlon Bergman, an assistant professor of medical ethics at the University of Pennsylvania, argues that AI-driven medical tools need a licensing system. He points to Utah’s recent pilot with the AI c…